Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2018

Accounting Policies [Abstract]

Schedule of Manufacturing Contingent Milestone Payments

The Company is also subject to certain contingent milestone payments, disclosed in the following table, payable to the Company’s manufacturer of its nebulizer used to administer Molgradex. In addition to these milestones, the Company will owe a royalty to the manufacturer of its nebulizer based on net sales. The royalty rate ranges from three and a half percent (3.5%) to five percent (5%) depending on the device technology used by the Company to administer the product.

Manufacturing Contingent Milestone Payments (in thousands):

	March 31, 2018
Molgradex API manufacturer:
Delivery of working and master cell banks	$	600
Achievement of certain milestones related to    regulatory approval of Molgradex		2,000
Molgradex nebulizer manufacturer:
Achievement of various development activities and    regulatory approval of nebulizer utilized to administer    Molgradex		8,628
Total manufacturing commitments	$	11,228